Informations:
Erreur:
ID
34421
Description
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01360554
Lien
https://clinicaltrials.gov/show/NCT01360554
Mots-clés
Versions (1)
- 17/01/2019 17/01/2019 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
17 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
evidence of pathologically confirmed, advanced nsclc (with known histology).
boolean
ID.2
Item
prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced nsclc).
boolean
ID.3
Item
adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.
boolean
ID.4
Item
adequate renal, hematologic, liver function.
boolean
ID.5
Item
ecog ps of 0-2.
boolean
ID.6
Item
radiologically measurable disease.
boolean
ID.7
Item
small cell histology.
boolean
ID.8
Item
symptomatic brain mets or known leptomeningeal mets.
boolean
ID.9
Item
prior therapy with agent known or proposed to be active by action on egfr tyrosine kinase or other her family proteins.
boolean
ID.10
Item
uncontrolled medical disorders.
boolean